Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Cardiovascular Effects of NSAIDs: A Review With a Focus on RA Patients
Author(s): Eirik Ikdahl , Anne Kerola , Eli Sollerud , et al Added: 1 year ago

Prevention & Chronic Conditions
Oral P2Y12 Inhibitors and Drug Interactions
Author(s): Elisabetta Bigagli , Jacopo Angelini , Alessandro Mugelli , et al Added: 10 months ago

Anticoagulation

Prevention & Chronic Conditions
Cardiovascular Drug Interactions with Nirmatrelvir/Ritonavir for COVID-19
Author(s): Andrea Di Lenarda , Nicola Ferri , Massimiliano Lanzafame , et al Added: 1 year ago

COVID-19

CV Disease in Special Populations
ESC 25: SWEDEPAD 1 and 2
Author(s): Marten Falkenberg , Joakim Nordanstig Added: 7 months ago
ESC Congress 2025 - Paclitaxel-coated devices in critical limb threatening ischemia were not effective in preventing amputation, nor improving quality-of-life in intermittent claudication.Dr Mårten Falkenberg (Sahlgrenska University Hospital, Gothenburg, SE) and Prof Joakim Nordanstig (Sahlgrenska University Hospital, Gothenburg, SE) join us to discuss findings from the SWEDEPAD 1 and 2 parallel… View more

Intervention

Vascular Disease and Surgery
Author(s): Byoung Geol Choi , Seung-Woon Rha , Se Yeon Choi , et al Added: 1 year ago

Anticoagulation
30th Annual Meeting of the ISCP
Author(s): Beatriz Nieves Ureña , Raúl Ptaszynski Lanza , Raúl Ludeña , et al Added: 1 week ago

Prevention & Chronic Conditions

Electrophysiology & Arrhythmia
ACC 25: The SMART-CHOICE 3 Trial
Author(s): Joo-Yong Hahn Added: 1 year ago
ACC 25 - SMART-CHOICE 3 Trial finds clopidogrel monotherapy to be the optimal anti-thrombotic strategy in high risk patients with contemporary drug-eluting stents.Dr Joo-Yong Hahn (Samsung Medical Center, Seoul, KR) joins us onsite at ACC Conference 2025 to discuss the findings from the SMART-CHOICE 3 study (NCT04418479). The study aims to evaluate the efficacy and safety of clopidogrel… View more

Anticoagulation

Intervention
ECO 24: Semaglutide in Body Weight & Reversion of Normoglycaemia: STEP 10
Author(s): Barbara McGowan Added: 1 year ago
ECO 2024 — Prof Barbara McGowan (Guy's and St Thomas' Hospital & King's College, UK) joins us to discuss the findings from the STEP 10 trial (NCT05040971, Novo Nordisk).This Phase 3 randomised clinical trial investigated the efficacy and safety of subcutaneous semaglutide 2.4 mg (GLP-1 RA) in 181 participants with obesity (BMI greater than or equal to 30.0 kg/m^2) and prediabetes. The primary… View more

Prevention & Chronic Conditions

Cardiovascular Kidney Metabolic
Systematic Scoping on DOACS in NVAF Patients
Author(s): Shirley Siang Ning Tan , Wei Hong Lai , Lee Len Tiong , et al Added: 8 months ago

Anticoagulation

Electrophysiology & Arrhythmia
Ibrutinib, Venetoclax and Adverse Cardiovascular Events
Author(s): Roberta Esposito , Pierantonio Menna , Emanuela Salvatorelli , et al Added: 6 months ago

CV Disease in Special Populations

Prevention & Chronic Conditions